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Executive Summary 
Background 
Over the past several decades, the impairing effects of alcohol on driving have become common 
knowledge. More recently, the use of illicit drugs such as cocaine, cannabis and methamphetamine 
have become the focus of increasing concern for its impact on road safety. However, it is less well 
understood that some psychoactive prescription drugs can also affect driving. Psychoactive prescription 
drugs, such as opioids, sedative-hypnotics and stimulants, are associated with serious harms 
including injury and death. In an effort to address these and other harms, the Canadian Centre on 
Substance Abuse (CCSA), together with over 40 partners, released First Do No Harm: Responding to 
Canada’s Prescription Drug Crisis, a 10-year pan-Canadian strategy that outlines 58 recommendations 
for collective action in a number of key areas, including prevention, education, treatment, monitoring 
and surveillance, enforcement, and legislation and regulation. 
The current review explores the extent to which psychoactive prescription drugs can adversely affect 
the cognitive and motor functions essential for the safe operation of a motor vehicle and thereby 
increase the risk of crash involvement. More specifically, the objectives of this report are:  
 To review and summarize the scientific literature on the impairing effects of psychoactive
prescription drugs on the skills and abilities required to operate a vehicle safely;
 To examine the epidemiological evidence on the extent to which psychoactive prescription
drugs are used by drivers and increase the risks of crash involvement; and
 To identify approaches for enhancing the safety of drivers who use psychoactive prescription
drugs in Canada.
The evidence reviewed in this report will help to inform policies and practices aimed at reducing 
injuries associated with driving impairment involving psychoactive prescription drugs.  
Method 
A search of scientific journals and grey literature was conducted using a combination of key terms 
and phrases to identify papers related to the effects of common psychoactive prescription drugs on 
driving as well as the prevalence and risks associated with these drugs in relation to driving. 
Findings 
Psychoactive prescription drugs cause changes in brain functioning. Such changes can disrupt normal 
cognitive and psychomotor performance through a variety of mechanisms. For example, depressant 
drugs slow the speed at which the brain receives, processes and responds to environmental 
information, reduce the effectiveness and efficiency with which decisions are made and impact 
motor control. On the other hand, stimulant drugs speed up brain activity and can create a situation 
where decisions are made impulsively, greater risk is taken, and normal sleep and rest periods are 
disrupted. As the stimulant drug’s effects wane, fatigue and sleepiness effects can cause inattention 
and carelessness. Although the manifestation of drug effects varies, the different mechanisms have 
the same net effect: a decrease in the quality of cognitive and psychomotor effort that goes into the 
driving task, creating substandard driving performance and elevating the risk of crash involvement. 
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The consequences of driving while impaired by psychoactive prescription drugs are becoming 
increasingly evident. Numerous studies that have examined the results of toxicological tests on the 
blood of drivers involved in serious road crashes have found evidence of psychoactive prescription 
drug use. In particular, drugs that slow the function of the brain in a manner similar to that of 
alcohol, such as sedatives and tranquilizers, are the drugs most often detected. In addition, it is not 
uncommon that these drivers have combined medications with other prescription drugs, illegal 
drugs, alcohol or combinations of all three. 
Determining the degree of risk posed by drivers who have used psychoactive prescription drugs can 
be challenging. Despite a variety of factors that limit the validity of the findings of these studies, the 
weight of the evidence indicates that the use of sedative drugs increases a driver’s risk of crash 
involvement. This increase is particularly a concern within the first two weeks of a patient starting a 
medication. Some hypnotic medications and opioid pain relievers have also been shown to be associated 
with increased crash risk in some circumstances. In many of these studies, it is not known whether the 
drug was prescribed by a healthcare professional and taken as directed, or used illicitly. 
Discussion 
Even in the absence of a complete understanding of the role of psychoactive prescription drugs in 
road crashes, there is sufficient evidence to begin implementing policies and practices to reduce the 
road safety risks posed by the use of these medications. Existing controls and regulations governing 
the distribution of prescription drugs provide considerable opportunities for prevention. Products 
could be systematically tested for impairment potential. Healthcare professionals could provide 
patients with specific information about the advisability or safety of driving while taking specific 
products. Product labelling could be standardized, providing clear guidance to consumers. The way 
forward requires interdisciplinary involvement in discussion and consultation to develop and implement 
an integrated set of policies and practices to reduce the road safety risks associated with the use of 
psychoactive prescription medications. The First Do No Harm strategy provides a forum and network 
for such discussions and collective action. 
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Introduction 
Psychoactive prescription drugs can have a beneficial impact on health and well-being. Pharmacological 
research is continually developing new medicines to treat a host of ailments and alleviate the 
symptoms of others. Unfortunately, some of these same medications can have adverse effects, 
particularly when used improperly. For example, opioid pain relievers, stimulants and sedative-
hypnotics are associated with a risk of adverse effects and harms, which can include addiction, 
overdose and death, all of which place a significant burden on health care, social services and public 
safety systems (National Advisory Committee on Prescription Drug Misuse, 2013). Physical and 
mental impairments from these drugs can also lead to unsafe driving and traffic crashes, resulting in 
injuries and deaths. This report explores the issue of impairment and crash risk associated with the 
use of psychoactive prescription drugs. 
In an effort to address the harms associated with psychoactive prescription drugs, the Canadian 
Centre on Substance Abuse (CCSA), together with over 40 partners, released a First Do No Harm: 
Responding to Canada’s Prescription Drug Crisis. This 10-year pan-Canadian strategy outlines 58 
recommendations for collective action in a number of key areas, including prevention, education, 
treatment, monitoring and surveillance, enforcement, and legislation and regulation. CCSA continues 
to provide leadership and coordination to ensure the effective implementation of the strategy.  
Over the past decade, the issue of drug-impaired driving has emerged alongside the persistent 
problem of alcohol-impaired driving. Although not necessarily a new problem, the use of drugs by 
drivers has come to the forefront of public attention most likely as a consequence of three factors. 
First, the number of deaths attributable to alcohol-impaired drivers continues to fall (Brown, Vanlaar, 
& Robertson, 2015). This fact does not suggest that the alcohol-crash problem has gone away, but 
after over 30 years of demonstrable progress, public interest has perhaps waned and has been re-
focused on a new priority — the influence of drug use on driving. Second, the growing number of 
jurisdictions that have legalized the use of cannabis for medical or recreational purposes or both has 
raised concerns about driving after cannabis use. Finally, recent changes in police enforcement practices, 
developments in oral fluid drug testing and increased drug testing of drivers involved in serious 
crashes have helped to identify drug-impaired drivers, highlighting the magnitude of the issue. 
For the most part, the focus of the attention afforded to drug-impaired driving has been on impairment 
as a result of the use of illicit substances such as cannabis and cocaine. However, drug impairment 
is not limited to the use of illicit substances. Many prescription drugs, as well as a variety of over-the-
counter (non-prescription) remedies, can also have adverse effects on a person’s ability to operate a 
vehicle safely. The potential of medicines to impair driving is not unfamiliar to Canadians. Some 
medications come with a label or package insert alerting the consumer that the product can cause 
“drowsiness” or “dizziness” and to avoid or “use caution” when driving or operating heavy machinery 
until the individual knows “how the medication will affect them.” Healthcare practitioners might also 
specifically advise their patients of the effects of certain medications on driving. The extent to which 
such warnings are given and patients heed them is unknown. 
To some degree, the potential for psychoactive prescription drugs to impair driving seems to have 
been assigned a lower level of concern among the public than driving after using illicit substances. 
Clearly, if a substance is illegal, it would be illegal to drive after its use. On the other hand, many 
drivers might mistakenly feel that unless told otherwise, a drug prescribed by their doctor is 
inherently safe. Accepting the fact that medications can have undesired adverse consequences that 
can compromise normal activities might be difficult for many to accept. Hence, to the extent their 
health condition permits, there is a tendency for people to continue their daily routines while taking 
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medications largely without concern that their medication might have an adverse effect on their 
ability to perform complex tasks such as driving, placing themselves and other road users at 
increased risk on the road.  
The use of prescription drugs is common among Canadians. According to Statistics Canada, 41% of 
Canadians aged 6 to 79 had taken at least one medication prescribed to them in the two days prior 
to the survey (Rotermann, Sanmartin, Hennessy, & Arthur, 2014). Among those aged 15–24, 26% 
reported using some type of prescription drug, and this increased to 83% among those between 65 
and 79 years of age (Rotermann et. al., 2014). Multiple prescription drug use was also found to 
increase with age (Rotermann et al., 2014).  
Not all prescription medications have the potential to impair the ability to operate a vehicle. In fact, 
the relatively high incidence of medication use among Canadians reflects use for the management of 
chronic medical conditions such as heart disease and diabetes (Rotermann et al., 2014); medications 
for these conditions have no apparent adverse effect on road safety when used as directed. The 
focus of this report is the use of psychoactive pharmaceuticals — that is, those that have effects on 
brain function. These drugs include opioid pain relievers, sedative-hypnotics and stimulants. These 
drugs have effects that can alter one’s state of alertness, motor performance and cognitive functioning, 
even when used as prescribed. The adverse effects, however, can be particularly profound when 
taken with other medications or alcohol or both. While certain psychoactive over-the-counter cold 
medications and sleep aids, as well as drugs for the relief of allergy symptoms (e.g., antihistamines) 
might also cause impairment, they are not a focus of this review.  
Whether the person using the drug was prescribed it by his or her physician, accessed it from friends 
or family, or purchased a diverted product from someone else, the impact can be the same. The 
primary difference is the reason for use. Whereas most individuals who use psychoactive prescription 
drugs are seeking the health benefits of medications, the goal of other individuals is often to 
experience the euphoria associated with many of these drugs or to escape withdrawal. To this end, 
these latter users often consume higher doses of the drugs or do so with greater frequency or both. 
This type of use can produce significant impairment and adverse effects, especially when used in 
high doses.  
These effects can also occur among those who use prescription medications for health reasons. 
Recent studies show very poor rates of compliance with prescription directions in some patient 
populations such as those with chronic pain (Couto, Romney, Leider, Sharma, & Goldfarb, 2009). 
Taking additional doses of prescribed medications, using medications prescribed to someone else, 
and using multiple medications or combining them with alcohol are not uncommon behaviours. The 
adverse effects of medications on driver behaviour, whether caused by ingestion to experience the 
pleasurable effects or double-dosing in an attempt to enhance or prolong the therapeutic effects, are 
qualitatively similar. For this reason, the primary focus of this report is on the potential impairing 
effects of psychoactive prescription drugs that are primarily intended for the treatment of a health 
condition, regardless of the circumstances or pattern of use.  
This paper reviews the extent to which psychoactive prescription drugs can adversely affect the 
cognitive and motor functions essential for the safe operation of a motor vehicle and thereby 
increase the risk of crash involvement. More specifically, the objectives of this report are:  
 To review and summarize the scientific literature on the impairing effects of psychoactive
prescription drugs on driving;
 To examine the epidemiological evidence on the extent to which psychoactive prescription
drugs are used by drivers and increase the risks of crash involvement; and
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 To identify approaches for enhancing the safety of drivers who use psychoactive prescription 
drugs and reducing the incidence of impaired driving related crashes and injuries in Canada. 
This report is intended for health and road safety professionals, policy makers and researchers, and 
will help inform policies and practices aimed at reducing injuries associated with driving impairment 
involving psychoactive prescription drugs. Based on its review of the current evidence, the report 
concludes with a discussion of program and policy options that could be explored to help reduce the 
risks associated with the use of psychoactive prescription drugs and driving. 
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Method  
A search of the published literature was conducted using a combination of key terms and phrases. 
(See Appendix A for the list of search terms that were used.) Databases such as PubMed, Cochrane 
summaries, Safety Lit, and Health Evidence were searched to identify papers published between 
2010 and 2015 related to (1) the effects of psychoactive prescription drugs on driving or driving-
related skills and abilities; and (2) the epidemiology (prevalence and risks) of psychoactive prescription 
drug use in relation to motor vehicle crashes. The initial search identified a set of 165 articles. 
Further searches included a wider time span (2000–2015) and specific drug names. Reference lists 
of identified papers were scanned for additional relevant articles.  
To locate grey literature, including technical reports and other publications, web sites of key 
organizations and groups (e.g., Canadian Association of Mental Health, National Highway Traffic 
Safety Administration, National Institute on Drug Abuse, DRUID, SafetyLit) and Internet search 
engines such as Google Scholar and Bing, were used. In addition, the collected proceedings of the 
International Conference on Alcohol, Drugs and Traffic Safety were searched for relevant literature.  
Titles and abstracts were reviewed for relevance and those that were deemed out of scope or that 
involved prescription drugs not available in Canada or not commonly detected in drivers involved in 
crashes (e.g., antipsychotics) were eliminated from further consideration. 
Rather than present a review of individual prescription drugs, drugs were grouped into the following 
categories according to the general similarity of their effects, not necessarily their pharmacological 
classification: sedative-hypnotics (e.g., benzodiazepines and the non-benzodiazepine hypnotics, 
zopiclone and zolpidem),1 central nervous system (CNS) stimulants (e.g., amphetamines) and opioids. 
Over-the-counter antihistamines have been included as well. It should also be noted that although 
cannabis for medical purposes is available in Canada, it was not included in the present review. (For 
a review of cannabis and driving, see Beirness & Porath-Waller, 2015.) 
For each category of substance, the review includes information on the general effects of the drugs 
and those effects specifically related to the cognitive and motor skills and abilities needed for the 
safe operation of a motor vehicle. In addition, where data exist, the extent of the effects in relation to 
dose, acquired tolerance and the interaction among various substances was also examined to better 
understand the types of impairments and the conditions under which impairment is either enhanced 
or mitigated.  
                                                 
1 Zopiclone and zolpidem are sometimes referred to as Z-drugs or Z-hypnotics. 
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Findings 
An understanding of the role of psychoactive prescription drugs in motor vehicle crashes requires 
evidence from two complementary lines of research, experimental and epidemiological. The role of 
experimentation is to document the nature and extent of deficits in cognitive and motor functioning 
produced by various doses of specific drugs. The role of epidemiological research is to determine the 
extent to which the type and amount of specific drugs are associated with, and contribute to, motor 
vehicle crashes. It was complementary and converging evidence from these two research approaches 
that firmly established the link between alcohol and road crashes. The same approach is currently 
being applied to drug-impaired driving.  
Establishing the connection between drugs and road crashes, however, has proven to be considerably 
more complex than for alcohol. For example, alcohol is a relatively simple molecule that can be readily 
detected and measured in breath samples. In addition, the absorption, distribution and elimination 
(i.e., the pharmacokinetics) of alcohol are relatively straightforward and well-understood. On the 
other hand, virtually all other drugs of interest require a sample of blood, urine or oral fluid to be 
collected and sent to a toxicology laboratory for analysis to determine their presence and concentration. 
The pharmacokinetics of drugs are considerably more complex than those for alcohol and can 
involve very different patterns of absorption and distribution, the production of active metabolites, 
and long and variable elimination rates. 
Drug effects can also vary between individuals depending on the dose, route of administration, 
concomitant use of other medications and/or alcohol, time of day, demographic characteristics (e.g., 
age, sex), and health status of the individual. In the case of prescription drugs, it is important to 
examine drug effects on healthy volunteers, as well as a sample of patients with the condition the 
medication is used to treat, both before the drug regimen has been initiated as well as after the 
patient has been stabilized on a therapeutic dose of the medication. Of particular relevance is an 
examination of the effects following initial use of the drug, as well as after a stable dose has been 
used for a period of time. This dual examination is required because tolerance to the acute effects of 
some drugs can develop with longer term use, minimizing or even eliminating some of the adverse 
effects on driving.  
A wide variety of psychoactive prescription drugs disrupt the release or reabsorption of neurotransmitters 
in the brain, which can affect normal cognitive and psychomotor functioning. Depending on the 
particular drug and the site of action, this effect can have an impact on alertness, perception, 
concentration, impulse control, the speed at which the brain receives, processes and responds to 
environmental information, and higher order executive functions such as planning, problem-solving, 
organizing and reasoning (Julien, Advokat, & Comaty, 2008). All of these mechanisms can adversely 
affect the quality of mental and physical effort dedicated to the driving task, decreasing performance 
and increasing the risk of crash involvement.  
The following sections review the evidence from experimental and epidemiological studies relevant 
to the impact of psychoactive prescription drugs on driving. 
Experimental Evidence 
Driving is a complex task that requires the coordination of a number of cognitive, perceptual and 
motor skills. Michon (1985) outlines three levels of skills and controls involved in driving: operational, 
tactical and strategic.  
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The operational level involves vehicle control skills: steering, braking, tracking, accelerating, 
decelerating, manipulating vehicle controls and automatic response patterns. These are the 
fundamental skills required to operate a vehicle. These behaviours must be learned prior to 
integrating other higher order driving skills.  
The tactical level involves manoeuvering skills required for complex action patterns that allow the 
driver to negotiate the variabilities in the roadway environment. For example, it involves guiding the 
vehicle through traffic, avoiding obstacles, changing lanes, maintaining headway, adjusting speed 
and overtaking. Actions at this level are expected to meet the goals set at the strategic level and 
adapt to circumstances or the outcome of specific manoeuvers.  
The strategic level involves planning, route selection, assessment of risks and benefits, critical 
judgment and dynamic evaluation of the environment, the traffic and the vehicle. At this level, the 
tasks are primarily cognitive and involve higher order analytical functioning.  
Most people are able to learn to integrate the various skills and functions necessary to operate a 
vehicle safely. With experience, these behaviours can become routine and automatic. However, for 
even the most proficient drivers, drugs and alcohol can adversely affect the efficient integration and 
application of these skills.  
Experimental studies of the effect of drugs on driving behaviour typically examine performance on 
tasks that assess the same or similar skills necessary for the safe operation of a motor vehicle: for 
example, tracking, reaction time, divided attention. The inherent artificial nature of the tasks often 
leads to questions pertaining to their relevance and validity in relation to actual driving. Driving 
simulators provide greater perceived validity in that they involve physical and cognitive tasks resembling 
those actually involved in driving. Driving simulators have become increasingly sophisticated, providing 
a more realistic experience of operating a vehicle (e.g., National Advanced Driving Simulator) and 
have become popular as a means to assess behaviour in as realistic a manner as possible, while 
eliminating the real risks of a traffic environment. A unique approach used at the University of Maastricht 
in the Netherlands involves conducting drug-impaired driving research in an instrumented vehicle on 
actual roadways (e.g., Ramaekers, Robbe, & O’Hanlon, 2000). Regardless of the approach, all of 
these studies provide insight into the effects of drugs on the skills and abilities required to operate a 
vehicle safely.  
Sedative-Hypnotics 
The types of drugs in this category have effects similar to those of alcohol. This category includes 
drugs that have relaxing, anxiety-reducing or hypnotic actions and are commonly used in the treatment 
of anxiety and insomnia. The general effects of sedative-hypnotics produce a reduction in neural 
activity and slowed neurotransmission. These effects result in slower reactions to stimuli, slower 
response times, poor coordination and impaired ability to divide attention. Two different types of 
drugs are discussed: benzodiazepines (e.g., diazepam, alprazolam, lorazepam) and non-
benzodiazepine hypnotics (e.g., zolpidem, zopiclone).  
Benzodiazepines  
A variety of benzodiazepines are available in Canada. They differ in terms of their efficacy in treating 
anxiety, muscle tension, seizures and insomnia, and producing sedation. Benzodiazepines also differ 
in their duration of action with some having relatively long periods of action (i.e., half-life2 from 40 to 
                                                 
2 The half-life of a drug is the time required for the concentration of drug in the body to be reduced by one-half. It is generally taken as an 
indication of relative duration of drug action. 
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100 hours) while others are metabolized and rendered inactive relatively quickly (i.e., half-life 2.5–
12 hours) (Julien et al., 2008).   
In general, benzodiazepines produce a state of relaxation and drowsiness. They can also cause 
confusion and disruption of short-term memory. These effects can produce dose-related motor and 
cognitive impairments similar to those caused by alcohol use and can interfere with the ability to 
operate a vehicle safely. 
Quantitative assessments of benzodiazepine effects on driving have been performed for alprazolam, 
showing significant driver impairment from both immediate release and extended release formulations, 
most notably weaving within the traffic lane and decreased alertness (Verster, Volkerts, & Verbaten, 
2002; Verster & Volkerts, 2004a; Leufkens, Vereeren, Smink, van Ruitenbeek, & Ramaekers, 2007). 
Assessment of the relationship between benzodiazepine concentrations in blood and the subject’s 
performance in field tests for impairment showed a positive correlation between diminished 
performance and increasing drug concentration (Smink, Lusthof, de Gier, Uges, & Egberts, 2008; 
Boucart, Waucquier, Michael, & Libersa, 2007; Bramness, Skurtveit, & Mørland, 2002, 2006). 
A meta-analysis of the effect of sleep medications on driving the morning after use (10–11 hours 
after initiating sleep) showed the use of long-acting benzodiazepines produced significantly greater 
variation in vehicle lane position compared to performance later the same day (Roth, Eklov, Drake, & 
Verster, 2014). A double dose also produced significant driving impairment in the afternoon following 
use (16–17 hours after initiating sleep).  
Non-Benzodiazepine Hypnotics 
A related group of drugs used for treating insomnia includes zolpidem and zopiclone, often referred 
to as “Z-hypnotics.” As would be expected, these drugs induce sedation and promote sleepiness, 
which serve to reduce sleep latency and improve sleep maintenance. Clearly, these effects are 
inconsistent with the safe operation of a motor vehicle. These drugs have a relatively rapid onset of 
action (30–90 minutes) and are intended to be taken at bedtime to facilitate sleep. Administration of 
these products at other times is not recommended.  
While these medications are very effective in enhancing sleep onset and maintenance, there is clear 
evidence of dose-related psychomotor and cognitive impairments shortly after administration 
(Gustavsen, Hjelmeland, Bernard, & Mørland, 2012). Perhaps more importantly, there is concern 
about residual effects following a period of sleep, typically the next day. A number of studies have 
examined the effect of these medications on driving the day after use (Gunja, 2013; Leufkens, Lund, 
& Vermeeren, 2009; Mets et al., 2011; Roth et al., 2014; Staner, et al., 2005; Vermeeren, et al., 
2014; Verster, Volkerts, Olivier, Johnson, & Liddicoat, 2007). Systematic reviews and meta-analyses, 
including many of these studies, reveal significant driving impairment the morning after administration 
of zopiclone following a full night’s sleep. Zolpidem showed no adverse residual effects on driving 
performance. Administration of either zopiclone or zolpidem in the middle of the night (typically after 
a period of unsuccessful attempts to sleep) produced significant driving impairment the following 
morning. Higher doses were associated with greater driving impairment (Leufkens & Vermeeren, 
2014; Verster, Veldhuijzen, Patat, Olivier, & Volkerts, 2006). 
A phenomenon known as “sleep driving” has also been reported with this class of drugs (Doane & 
Dalpiaz, 2008; Paulke, Wunder, & Toennes, 2015; Poceta, 2011; Pressman, 2011). This condition, 
characterized by unconscious driving, without intent and with no recollection of the activity, is 
controversial and has only been reported anecdotally. These individuals are often stopped by the 
police and arrested for impaired driving. Case reports indicate a number of related factors including 
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daytime use of the drug, high blood drug concentrations, use of other medications, concomitant 
sleep disorders and a history of parasomnia. 
Opioids  
Opioids include the naturally occurring opiates morphine and codeine, semi-synthetic variants, 
including oxycodone, oxymorphone, hydrocodone, hydromorphone, dihydrocodeine and buprenorphine, 
and synthetic opioids such as methadone, propoxyphene, fentanyl, tramadol and meperidine. The 
opioids reduce sensitivity to pain, and are widely used to relieve acute and chronic pain. The opioids 
also act on the cough centre in the brain stem and are used as a cough suppressant. The most 
important use of the opioids outside of the CNS is to relieve diarrhea through their effect on the 
intestine (Julien et al., 2008). 
Opioids depress CNS and respiratory function and induce sedation and sleep. This reduced level of 
consciousness, which can accompany the loss of the ability to feel pain (analgesia), especially with 
higher doses or in non-tolerant individuals, can result in impaired performance in tasks demanding 
cognitive and psychomotor skills such as driving. Pupillary constriction, which is common with opioid 
use, can affect vision and light/dark adaptation.  
Chronic pain itself can be an impairing medical condition. Nilsen and colleagues (2011) examined 
driving simulator performance among a group of individuals with untreated chronic pain, a group 
with chronic pain treated with codeine and a group of healthy controls. Those with chronic pain, 
whether treated with codeine or not, performed more poorly than the group of healthy controls, 
suggesting that the impairment was related to chronic pain and was not a function of codeine.  
Tolerance to the effects of opioids is well documented, and there is some evidence that patients 
stabilized on moderate doses of opioids have tolerance to some of the impairing effects of the drugs 
on cognitive and psychomotor functioning (Byas-Smith, Chapman, Reed, & Cotsonis, 2005; Fishbain, 
Cutler, Rosomoff, & Rosomoff, 2003; Soyka, 2014; Zacny, 1995). A systematic review of studies of 
patients on opioid maintenance therapy concluded that while opioid-naïve subjects (i.e., new users) 
were subject to impairment, only some opioid maintenance patients showed slight driving impairment 
and others showed no impairment (Strand, Fjeld, Arnestad, & Mørland, 2013).  
It typically takes several days on a stable dose to acquire the tolerance necessary to counter the 
drug’s effects (Gringauz, Rabinowitz, Stav, & Korczyn, 2001). Changes in dose or frequency of 
dosing, breaks in dosing or co-administration with other opioids, however, restores the potential for 
impairment. Patients being treated for chronic pain conditions often take other drugs in combination 
with opioids, such as muscle relaxants, sleep aids and anti-depressants, which can combine with the 
effects of the opioid to produce greater impairment.   
In summary, therapeutic use of opioids by a naïve user, problematic opioid use even in a tolerant 
user, or combining opioids with other CNS depressant drugs or alcohol create a significant risk of 
driving impairment. Supervised chronic administration with a stable dose does not appear to create 
significant risk of impairment. 
Central Nervous System Stimulants  
Prescription drugs in this class include amphetamines and methylphenidate, most commonly used to 
treat attention deficit/hyperactivity disorder (ADHD). Amphetamines are also used in the treatment 
of narcolepsy. In the past, amphetamines have also been used as an appetite suppressant to 
promote weight loss and as a fatigue-reducing agent to help maintain wakefulness and vigilance 
over extended periods of time.  
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Amphetamines cause a lessening of fatigue, an increase in mental and motor activity, an elevation 
of mood, and a general feeling of well-being. However, their indiscriminate use in attempts to 
increase capacity for work or to overcome fatigue is undesirable and not necessarily effective. At 
high doses, amphetamines produce a euphoria that upon abrupt withdrawal of the drug reverts to 
severe depression and lethargy. 
Amphetamines produce a range of effects on drivers that differ in the acute phase (shortly after drug 
consumption) and the post-acute phase, when drug withdrawal or abstinence syndrome can be an 
issue (Logan, 2002). With higher doses of amphetamine, the immediate effects of stimulant use 
produce intense excitement and euphoria, which can be distracting and disorienting, affecting the 
degree of attention and concentration on driving. The drugs also produce changes in reaction time, 
often resulting in faster but less reasoned, more impulsive responses and increased risk taking. 
Higher doses or chronic use can produce agitation, hyper-vigilance and irritability. Some of the motor 
effects of the drug result in restlessness, a need to be in constant motion, and problems with balance 
and coordination. Following intense stimulant use, susceptible individuals can develop paranoia, 
hallucinations and delusions (Blaho, Logan, Winbery, Park, & Schwilke, 2000).  
At low doses, stimulants can offset fatigue and delay the need for sleep (Caldwell, Smythe, Leduc, & 
Caldwell, 2000). However, the administration of amphetamine does not compensate for the 
detrimental effects of sleep deprivation (Hjalmdahl et al., 2012). The chronic sleep loss resulting 
from repeated use creates a rebound or withdrawal effect when drug use stops. Those individuals 
who use stimulants who are experiencing withdrawal suffer fatigue, extreme sleepiness, anxiety, 
exhaustion, drug craving, irritability and dysphoria (Logan, 2002). In some respects, this withdrawal 
phase is similar to the effects caused by CNS depressant drugs, and can have profound effects on 
driver attention and performance. The range of effects can vary dramatically among individuals 
depending on dose, route of administration, intensity of use and time since last use.  
A number of studies have examined the effects of amphetamines and methylphenidate on the driving 
performance of individuals with ADHD (Biederman et al., 2012; Cox et al., 2008; Gobbo & Louzã, 
2014; Kay, Michaels, & Pakull, 2009; Sobanski et al., 2008). These studies report that therapeutic 
doses of amphetamine or methylphenidate can improve driving performance and information 
processing, and reduce driving errors compared to that of untreated patients. However, 16 hours 
after administration of amphetamine, inattentive on-road driving errors increased, suggesting a 
possible rebound effect (Cox et al., 2008). In healthy volunteers, amphetamine improved various 
aspects of attention and suggested possible enhancements in tracking (Silber et al., 2005).   
In summary, individuals with untreated ADHD have been shown to exhibit impulsive, fast and 
aggressive driving behaviours (Barkley & Cox, 2007). The evidence indicates that compliant 
physician-supervised therapeutic use of the methylphenidate or amphetamines can improve driver 
performance in individuals with ADHD (Jerome, Habinski, & Segal, 2006). Inappropriate or 
problematic use of stimulants, including the use of amphetamines in an attempt to compensate for 
driver sleepiness, can result in impulsive, erratic behaviour, and can be followed by a period of 
depression and dysphoria that can have detrimental effects on driving.  
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Antihistamines  
Antihistamine medications such as diphenhydramine and chlorpheniramine are readily available in a 
variety of over-the-counter medications used to treat the symptoms of allergies, common colds, insomnia 
and motion sickness. These medications can induce sleepiness, sedation and loss of sustained 
attention (Verster & Volkerts, 2004b), effects similar to those of sedative-hypnotics described in a 
previous section. So-called “first generation” antihistamines such as diphenhydramine are well-
established as having the ability to cause impairment in driver ability (Burns & Moskowitz, 1980; 
Moskowitz & Wilkinson, 2004). These drugs are often combined with other drugs (e.g., dextro-
methorphan) in multi-symptom cold relief formulations that can also produce impairment or drowsiness 
(Logan 2009). Newer antihistamines such as fexofenadine have been shown to produce less sedation 
and fewer impairing effects (Ridout & Hindmarch, 2002; Tashiro et al., 2005; Perttula et al, 2014).   
Summary 
Psychoactive prescription drugs produce changes in the brain that disrupt normal cognition and 
psychomotor skills. They produce these changes occurs through a variety of mechanisms. For 
example, sedative-hypnotics slow the speed at which the brain receives, processes and responds to 
environmental information, reduce the effectiveness and efficiency with which decisions are made, 
and impact motor control. On the other hand, high doses of CNS stimulants can cause over-stimulation 
of the brain and create a situation where decisions are made impulsively, greater risk is taken, and 
normal sleep and rest periods are disrupted. As the stimulant effects wane, fatigue and sleepiness 
cause inattention and carelessness. Although the manifestation of drug effects varies, the different 
mechanisms have the same net effect: a decrease in the quality of cognitive and psychomotor effort 
that goes into the driving task, creating substandard driving performance that elevates the risk of 
crash involvement. 
Dose and route of administration can cause a difference in the intensity of effect, and tolerance to 
the drug can make it difficult to predict the specific level of effect in an individual drug-using driver. 
Prescription drugs, when used by a naïve user, after an increase in dose or when used in a problematic 
way, have the potential to cause impairment. Even responsible use of a medication in an individual 
who is non-tolerant or through interaction with other drugs or alcohol can create a dangerous decline 
in driving performance.  
Experimental research demonstrating the impairing effects of drugs is, however, only one piece of 
evidence implicating the potential of psychoactive prescription drugs as a risk factor for driving. It is 
also necessary to show that drivers use these substances and that these substances are used by 
drivers who become involved in crashes — that is, epidemiological evidence. The following sections 
provide a summary of the epidemiological studies in this area.  
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Epidemiological Evidence 
Two types of epidemiological evidence provide information about psychoactive prescription drugs 
and driving. Descriptive epidemiology examines the extent to which prescription drugs are used by 
drivers. This evidence includes random surveys of drivers on the road, as well as surveys of drivers 
involved in crashes. Analytical epidemiology examines the extent to which drivers who test positive 
for prescription drugs are over-represented in crashes. Both types of studies typically require drivers 
to provide a biological specimen for analysis of drug content.3 Breath samples have been used for 
many years to measure the concentration of alcohol in the blood. Breath samples are easily obtained 
and can be analyzed on site. There is also a good relationship between the concentration of alcohol 
in the blood and the extent of impairment. However, assessing drug use is considerably more complex. 
An assessment of drug use requires a sample of blood, urine or oral fluid that is sent to a toxicology 
laboratory for analysis. The choice of specimen is an important consideration. Blood is a preferred 
sample over urine. Blood analysis provides an approximation of active drug concentrations, which 
allows assessment of dose range, problematic or compliant use, and potential impairment. Blood 
drug concentrations, however, do not necessarily reflect drug concentrations in the brain, which is 
the site of psychotropic drug action. Hence, inferences about drug effects based on blood drug 
concentrations are subject to considerable variability.  
Urine is the least useful specimen in that it reflects recent drug use or exposure, but not necessarily 
active effects. Some drug metabolites can be detected in urine for hours or days after the acute drug 
effect has dissipated. In recent years, oral fluid has provided a means to collect relatively non-invasive 
samples, the results of which can be interpreted in a manner analogous to those of blood. Unfortunately, 
not all drugs transfer readily from blood to oral fluid (e.g., benzodiazepines) and hence their prevalence 
can be underestimated in oral fluid samples (Drummer, 2006).  
Roadside Surveys 
Roadside surveys have been done periodically in various countries over the past decades. First used 
to assess the extent of alcohol use by drivers, the roadside survey technique has evolved to include 
the collection of oral fluid samples (in addition to breath samples) to test for the presence of a variety 
of commonly used drugs (Boase, 2012). The technique involves randomly selecting drivers from the 
traffic stream and having them provide a sample of breath and oral fluid, the overall purpose of which 
is to provide an estimate of the prevalence of alcohol and drug use in a random sample of drivers.  
One of the earliest roadside surveys examining drug use by drivers was conducted by Krüger and 
colleagues (1995) in Germany. From the 2,235 oral fluid samples collected, it was determined that 
3.6% of drivers tested positive for benzodiazepines and 0.6% tested positive for cannabis. Among 
the 0.7% of drivers who tested positive for opiates, approximately three-quarters were suspected to 
have been the result of the use of medically prescribed codeine. Of some note, about one-third of all 
drug-positive cases were also found to be positive for alcohol. 
In 1999, the province of Quebec conducted the first roadside survey in Canada to assess driver drug 
use (Dussault, Lemire, Bouchard, & Brault, 2000). Just under half of all drivers selected agreed to 
provide a sample of urine to be tested for drugs. Although oral fluid was also collected, the results 
were not reported. Analysis of the urine samples revealed an 11.8% drug positive rate. Cannabis 
(6.7%) and benzodiazepines (3.6%) were the most commonly found substances. The relatively low 
                                                 
3 Pharmacoepidemiological or registry-based studies are an exception that, rather than using toxicological analysis of biological samples to 
determine drug status, instead use prescription records. 
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rate of compliance with the request for a urine sample, combined with the inherent problems in 
interpreting the road safety implications of urine drug tests, left questions about the validity of the 
findings from this study.  
These early studies were followed by a series of roadside surveys of alcohol and drug use by drivers 
in Scandinavia, Europe, South America, the United States and Canada. These surveys are summarized 
in Appendix B. In addition to the results for psychoactive prescription drugs, the results for alcohol 
and cannabis are presented for comparison purposes. 
In reviewing these studies, it should be noted that the methodological details of these surveys vary 
considerably across countries, for example in the time of day and days of the week when the surveys 
were conducted. Surveys also differ in the list of drugs included in the test panel and the detection 
limits of the drug tests. Response rates also vary. In several European countries, alcohol and drug 
tests are mandatory, with penalties for refusal. Consequently, response rates are very high. Other 
surveys are voluntary and drivers can elect not to participate with no repercussions. Hence, comparisons 
of the results across countries should be made with caution.  
Many studies report the prevalence of drivers who test positive for a variety of psychoactive prescription 
drugs, most notably benzodiazepines, opioids and amphetamines. It is difficult, however, to determine 
whether the substance was prescribed by a healthcare practitioner and used as directed. Although 
very high drug concentrations can generally be interpreted as some form of inappropriate use, 
concentrations within or below the therapeutic range cannot necessarily be equated with medicinal 
use.  
The information in Appendix B also does not include data on the use of more than one drug and/or 
use with alcohol. Such behaviour is not uncommon and the range of available combinations is large. 
Using more than one potentially impairing psychoactive prescription drug or combining these drugs 
with illicit drugs or alcohol adds to the potentially impairing effects. 
It is apparent from the roadside survey data presented in Appendix B that psychoactive prescription 
drug products are present in the general driving population. The range of prescription drugs detected 
by oral fluid screens is often limited to those most likely to have an adverse effect on drivers (e.g., 
benzodiazepines, opioids, stimulants and hypnotics). Some studies include tests for the presence of 
other substances such as antidepressants, anticonvulsants and antihistamines. It should also be 
noted that some substances of interest, most notably benzodiazepines, are difficult to detect in oral 
fluid. Furthermore, in the absence of additional testing, the mere presence of a drug should not be 
interpreted to mean that the driver was impaired. In light of the various limiting factors, roadside 
surveys provide, at best, an indication of the prevalence of the use of prescription drugs by drivers. 
Several general observations from the table are worth noting. Rates of alcohol and drug use by drivers 
in Europe tend to be lower than in Canada. To some extent, the difference could reflect the fact that 
European surveys tend to sample from the general driving population at all times of day and all days 
of the week, whereas in Canada roadside surveys are generally conducted from 9:00 p.m. to 3:00 
a.m. on Wednesday through Saturday nights, a reflection of the timeframe during which alcohol and 
recreational drug use among the driving population is most common. Distributing survey times 
throughout the week and including daytime data collection provides a more comprehensive and 
representative picture of the overall prevalence of alcohol and drug use by all drivers.  
Including weekdays and daytime hours in the data collection shows that alcohol use by drivers is not 
common during daytime hours, but serves to highlight the extent of psychoactive prescription drug 
use (e.g., benzodiazepines) by drivers during daytime hours and on weekdays (Lacey et al., 2009). 
Indeed, older drivers are more likely than younger drivers to test positive for prescription drugs 
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regardless of day of the week. This finding would suggest distinct and separate groups of individuals 
who use drugs and possibly different motivations for drug use. Further research is needed to uncover 
the characteristics of various subgroups of the population who drive after using different types of 
drugs. Such information will help efforts to develop targeted prevention messaging and initiatives.  
In roadside surveys conducted in Canada and the United States (Beirness & Beasley, 2009, 2010, 
2011, 2012; Beirness, Beasley, & McClafferty, 2015; Compton & Berning, 2015; Lacey et al., 2009), 
the proportion of drivers who test positive for alcohol has been decreasing over the past several years. 
However, the use of cannabis has been increasing. It is not known the extent to which this latter trend is 
associated with increased access to cannabis for medical purposes and changing policies (or perceptions 
thereof) towards the use of cannabis for non-medical purposes. In comparison, the reported prevalence 
of prescription drugs by drivers is relatively low. The most common classes of prescription drugs found 
among drivers are benzodiazepines and opioids. Once again, it is not possible to determine the extent to 
which the prevalence of these drugs in the driving population reflect appropriate medical use or whether 
the driving behaviour of these individuals was adversely affected by the presence of the drug.  
Drivers Involved in Crashes 
Numerous studies from around the world have examined the incidence of drugs and alcohol among 
drivers injured in crashes. In reviewing these studies, it is important to recognize that they use a 
diversity of methods, procedures, populations, sample sizes and case selection methods, and each 
of these factors can have an impact on the results. For example, low testing rates among drivers 
killed and injured in crashes continue to plague the search for a valid estimate of the prevalence of 
drug use among crash-involved drivers. In jurisdictions where such testing is not required, drivers 
who are injured in crashes are rarely tested without at least suspicion of drug or alcohol use. This 
limitation severely restricts the ability to determine the overall prevalence and contribution of 
substance use in crashes. Hence, attempts to estimate the overall prevalence of drug use among 
drivers involved in crashes from the existing studies should be done so with considerable caution.  
A summary of findings from studies from various countries that have examined the prevalence of 
psychoactive prescription drugs among drivers killed or injured in road crashes are presented in 
Appendix C. The results of studies in the countries that participated in the DRUID4 project in Europe 
are presented in Appendix D (Isalberti et al., 2011). In reviewing these tables, it should be noted that 
not all studies tested for the same drugs or necessarily reported the results the same way. The tables 
present the main drug categories of interest: benzodiazepines, Z-hypnotics (zopiclone, zolpidem), 
amphetamine and opioids. Antihistamines are rarely reported. Where amphetamine is included, it is 
recognized that there is a high likelihood that its use is illicit. The results for some substances have 
not been included in the tables (e.g., cocaine, antidepressants, acetaminophen).  
In most cases, it is not possible to infer that drivers who tested positive for specific substances were 
impaired at the time of crash involvement. A positive drug result merely indicates that the drug was 
consumed and that it was present in the driver’s blood at the time of testing, which can be several 
hours from the time of the crash. Some individual studies only report drug concentrations above a 
specified threshold value, particularly countries where per se drug limits5 have been established for 
specific substances (e.g., Norway). In such countries, drivers with a drug concentration in excess of 
the threshold would be deemed to have committed a driving violation.  
                                                 
4 The DRUID project is a large multi-site study in Europe. The formal title is Driving under the Influence of Drugs, Alcohol and Medicines. 
5 Per se limits specify a drug concentration above which it is an offence to operate a vehicle, similar to the 80 mg/dL limit in Canada for 
alcohol (see Canadian Centre on Substance Abuse, 2015). 
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A common finding in many studies was that drivers injured or killed in crashes tested positive for 
more than one type of drug. Prescription drugs could be combined with other prescription drugs, 
illicit substances and alcohol. The drug interactions from this pattern of use create a high-risk 
situation that is of concern not only for driving, but for health reasons as well.  
Not surprisingly, the findings from the studies on crash-involved drivers vary by study and by country. 
For example, whereas less than 2% of injured drivers in the Netherlands were found to have used 
potentially impairing prescription drugs (Legrand, Houwing, Hagenzieker, & Verstraete, 2012), these 
substances were found in a considerably higher proportion of drivers in Canada (Beirness, Beasley, 
& Boase, 2013; Jeffery, Hindmarsh, & Mullen, 1996; Stoduto et al., 1993) and the United States 
(Brady & Li, 2014; Romano & Pollini, 2013). The prevalence of benzodiazepines among crash-involved 
drivers in northern European countries is also higher than that in southern European countries 
(Isalberti et al., 2011). It is uncertain as to whether this reflects differences in drug use patterns or 
testing protocols. Whereas many countries have well-developed systems for the routine collection of 
bodily fluid samples from drivers killed in road crashes to test for alcohol, testing for other substances 
is less consistent. The testing for alcohol and drugs in drivers involved in non-fatal crashes is routine 
in some countries, while in others, ethical and privacy concerns often supersede the needs of research 
and enforcement. Nevertheless, such testing is critical for routine surveillance, monitoring trends 
and identifying emerging patterns in the substances involved in traffic deaths and injuries.  
The prevalence of psychoactive prescription drug use among serious or fatally injured drivers is 
generally less than that of alcohol and often less than that of cannabis. Nevertheless, prescription 
drugs that are known to have impairing effects are routinely detected in the blood of drivers involved 
in serious crashes. While such information provides valuable evidence of the extent to which 
prescription drugs are involved in road crashes, the key issue is not only how frequently drugs are 
detected among drivers, but the extent to which consumption of these substances contributed to the 
crash. The evidence pertaining to this issue is examined in the next section. 
Risk of Crash Involvement 
The risk of crash involvement associated with the use of specific drugs is determined by comparing 
the prevalence of drug use among drivers to that among drivers involved in crashes. Two primary 
approaches have been used to determine the risk associated with drug use among drivers: (a) case-
control studies and (b) crash culpability or responsibility studies. A third approach, referred to as 
pharmacoepidemiology or registry-based studies, has also been used to estimate the risk of crash 
involvement associated with the use of pharmaceuticals. All three approaches provide valuable 
information pertinent to the issue. This section examines the strengths and limitations of the various 
approaches and summarizes the evidence from studies that have used these methods.  
Methodological Issues  
The case-control methodology used in the study of drug-impaired driving is a direct extension of the 
method used to determine the relative risk of crash among drinking drivers, which in turn is an 
adaptation of the design from classic medical epidemiology. Cases are defined as drivers involved, 
injured or killed in road crashes. The frequency of drugs detected in the cases is compared to the 
frequency of drugs detected in a comparable group of drivers who have not been involved in crashes. 
The degree to which drugs are more frequently detected in crash populations is an indication of the 
extent to which drugs present an elevated risk for drivers.  
This method has been instrumental in understanding the risks associated with alcohol use by drivers. 
In addition, by comparing the quantity of alcohol used among cases and controls, it was possible to 
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determine the relative likelihood of crash at different blood alcohol concentrations (Blomberg, Peck, 
Moskowitz, Burns, & Fiorentino, 2009; Borkenstein, Crowther, Shumate, Zeil, & Zylman, 1964). Similar 
data are fundamental in determining which prescription drugs present an increased risk for drivers. 
The application of the case-control method to studying the risk of crash for drivers using drugs is 
somewhat more complex than for alcohol. First, unlike the situation involving alcohol, the testing for 
drugs, both among the cases and the controls, is more difficult. Ideally, blood should be obtained 
from both cases and controls, but obtaining the needed compliance from controls can be difficult 
and, as a consequence, testing rates can be low, producing unreliable estimates. Among cases, 
similar problems are experienced, but are often minimized in the case of fatalities. The net result is 
that the estimates derived from the comparison group often suffer as a result of missing data. 
Assumptions made about the distribution of drugs in the untested portion of the sample can have 
profound effects on the interpretation of the estimates of risk.  
Second, the type of sample (blood, oral fluid or urine) used to test for drugs has a strong bearing on 
the certainty that a substance poses a risk for crash involvement. Ideally, if a substance is detected, 
it should signify that it could reasonably be expected to have had an adverse effect on the driver at 
or around the time of the crash. Proving this assumption requires an indication of the level of active 
drug in the driver’s blood because the amount of a substance in blood provides the best indication of 
recent use and the extent of the potential influence on driver behaviour. The study of the role of 
alcohol in crashes has been greatly facilitated by the fact that blood alcohol levels can be easily and 
reliably established from breath samples. However, blood levels of other types of psychoactive 
substances cannot be easily established from breath samples and typically require that toxicological 
testing be conducted on bodily fluids. Because of the inherent difficulties in obtaining blood samples, 
particularly from control populations, many studies have used oral fluid as the medium for drug testing. 
Unfortunately, some drugs do not transfer well from blood into oral fluid (e.g., benzodiazepines), which 
can result in false negative results. In addition, although oral fluid drug concentrations are often 
correlated with blood concentrations, they are not necessarily equivalent, and direct comparisons of 
oral fluid and blood concentrations can be misleading. Nevertheless, oral fluid testing provides a 
means by which to determine at least drug prevalence in control populations, thereby greatly facilitating 
efforts to conduct these types of studies. 
A third methodological problem that complicates case-control studies is the elapsed time between 
the crash and the drawing of the specimen for drug analysis. The longer the period of time between 
the crash and the drawing of the sample, the greater the risk of underestimating the incidence and 
level of the drug.  
The case-control method requires the sample of crash-involved cases to be compared to a sample of 
drivers who have not been involved in crashes, matched on variables known to be differentially 
associated with crash involvement: for example, time of day, day of week, location and type of vehicle. 
Drivers selected for inclusion are usually volunteers and have the option of refusing to participate. 
Not surprisingly, some studies show that a substantial proportion of drivers elect not to cooperate 
with invasive procedures such as the collection of blood or urine samples. For example, in the Quebec 
study, 97% of drivers provided a breath sample, but only half (49.6%) agreed to provide a urine sample 
to test for the presence of drugs (Brault, Dussault, Bouchard, & Lemire, 2004). Some drivers might 
refuse because of fear of detection and prosecution; others might simply object to the invasiveness of 
the procedures or the amount of time required. It should be noted, however, that in several European 
studies (e.g., Ahlm, Björnstig, & Oström, 2005), very high response rates have been obtained. 
Undoubtedly, random testing laws and the use of police to conduct the survey served to enhance 
compliance. In any event, refusal rates that exceed the incidence of drug detection can compromise 
the validity of the comparisons.  
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The wide range of psychoactive drugs that can be studied mean that case-control studies require an 
extremely large number of crash-involved and crash-free drivers. Even when the drivers studied number 
in the thousands, the relatively low incidence of specific drugs means that drugs often have to be 
combined into groups with similar effects and comparisons are often reduced to a simple comparison 
of the presence or absence of the drug or drugs under investigation. Few studies have attempted to 
determine the extent of increased risk according to the quantity of drug found (Drummer, 2006; 
Laumon, Gadegbeku, Maint, Biecheler, & the SAM Group, 2005). 
Furthermore, should a substance be found to be over-represented in crashes, it cannot be assumed 
that the mere presence of the substance was sufficient to have contributed to the crash. In fact, the 
case-control approach merely provides evidence of an association between the drug and crash 
involvement, and does not imply that the substance induced a degree of impairment sufficient to 
have contributed to the crash. Other factors associated with drug use, such as the characteristics of 
the person or their driving style, could also explain the observed association (Terhune, 1986).  
An alternative approach, culpability analysis, also referred to as responsibility analysis, has been 
employed as a means to study the role of drugs and alcohol in motor vehicle crashes (Robertson & 
Drummer, 1994; Terhune, 1983, 1986). This approach does not require a non-crash-involved control 
group of drivers and includes information about the attribution of drivers’ responsibility for the crash. 
Judgments about responsibility for causing the crash are made by examining the circumstances and 
events leading up to the crash. Comparisons are then made between the proportion of drivers according 
to drug use status and crash responsibility. The contribution of drugs is determined by the extent to 
which a greater proportion of drug-positive drivers are deemed responsible for the crashes in which 
they were involved. 
Culpability analysis alleviates the difficulty of obtaining fluid samples from an appropriate sample of 
drivers not involved in crashes. At the same time, however, it loses valuable exposure information 
about the use of drugs by drivers who are exposed to risk, but have not been involved in a crash. 
Moreover, the design does not eliminate the challenges of obtaining a valid sample of crash-involved 
cases that have appropriate toxicological data derived from fluid samples obtained close in time to 
the crash. As well, the procedure is somewhat subjective and highly dependent on the method of 
rating crash responsibility, so it is critical that judgments about responsibility are made without 
knowledge of drivers’ use of alcohol or drugs, and that responsibility is assessed by applying a strict 
set of scoring criteria. Some studies, however, rely on judgements of responsibility made by the 
investigating police officer. Police judgments of crash responsibility are not necessarily reliable and 
might be biased by knowledge or suspicion of drug use by the drivers involved.  
Culpability analysis has been used successfully in the study of alcohol and driving, and such studies 
have consistently found alcohol to be associated with higher risk of crash involvement. Culpability 
analysis of the role of drugs in crashes provides another source of evidence.  
Pharmacoepidemiological studies, a variation of the classic case-control approach, have been used 
to study the role of prescription drugs in road crashes. These studies compare the incidence of crashes 
among drivers who have (cases) or have not (controls) been prescribed a specific psychoactive drug for 
the treatment of a disorder. Information from toxicological tests on drivers involved in crashes is not 
typically obtained or used in the analysis. Hence, it is not possible to verify that cases were actually 
taking the prescribed medication at the time of the crash, taking it as directed, or taking the medication 
in the absence of alcohol or other drugs. Nevertheless, the large sample sizes typically involved in 
these studies reduce the possibility of these factors having a significant influence on the overall 
results and can provide information about overall risks.  
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Summary of Risk of Crash Involvement Evidence 
Despite the limitations, all three types of studies provide valuable insights into the relationship between 
the use of prescription drugs and crash involvement. Appendix E presents a summary of these studies. 
The major findings are presented in terms of the odds ratio (OR) or relative risk (RR) of crash involvement 
associated with the major types of drugs examined in this report: sedative-hypnotics (benzodiazepines, 
non-benzodiazepine hypnotics), CNS stimulants (amphetamine, cocaine) and opioid pain relievers 
(morphine, codeine). Where available, the 95% confidence intervals are also presented.6 
Among the studies presented in Appendix E, the evidence on the risk of crash involvement associated 
with the use of psychoactive prescription drugs varies considerably. Although many studies reveal a 
statistically significant increase in risk, there are other studies that show the risk is no different than 
that associated with a driver who has consumed neither drugs nor alcohol. The different results could 
be a result of differences among studies, such as methods, population, country or region, sample 
size, testing rates and so on. These findings stand in marked contrast to those obtained by studies 
that have examined the use of alcohol consumption by drivers, which invariably show a level of risk 
that increases exponentially with the amount of alcohol consumed, regardless of the methods used 
by the studies (Blomberg, et al., 2009; Borkenstein, et al., 1964; Compton & Berning, 2015). Most 
studies examining crash risk associated with drug use have not been able to assess the differential 
risk associated with increasing drug concentration, but have only been able to separate drivers who 
test positive for the drug versus those who test negative. At most, one study has examined the crash 
risk associated with different prescribed doses of opioids (Gomes et al., 2013), but did not actually 
conduct tests to confirm the drug concentration.  
Benzodiazepines are among the most commonly prescribed medications, so it is not surprising that 
they are found among drivers on the road as well as among those involved in crashes. Among the 
studies that examined benzodiazepines, the weight of the evidence shows increased risk of crash 
associated with the use of benzodiazepines. The degree of risk, however, depends on the type of 
benzodiazepine and the duration of its use. For example, long-acting benzodiazepines were associated 
with higher crash risk than short-acting benzodiazepines. The risks were also higher within the first 
couple of weeks following the prescription (presumably the start of drug use), but the magnitude of 
the risk decreased with longer-term use (i.e., 61 to 365 days). This finding suggests that patients can 
develop a degree of tolerance to the impairing effects of the medication or can learn to adapt their 
behaviour so as not to be as susceptible to the adverse effects or both.  
Two studies provide evidence of increased risk associated with the use of zopiclone and zolpidem 
(Gjerde, Christophersen, Normann, & Mørland, 2011; Gustavsen et al., 2012). The experimental 
literature indicates that these hypnotic drugs can have impairing effects that linger into the morning 
after use of the drug at bedtime, suggesting that users have increased risk of crash involvement 
even after a night’s sleep. It is not clear, however, whether the reported risks are associated with 
“next morning” drug effects or with improper or recreational use.  
Evidence on the risks associated with the use of opioids is also mixed. The experimental literature 
shows opioids can cause impairment. It also shows that tolerance can develop to opioids relatively 
quickly with regular use of the same dose. Adherence to a program of medical use of prescription 
opioids would be expected to result in the development of some degree of tolerance. Tolerance could 
mitigate the extent of impairment and crash risk. In epidemiological studies, it is often difficult to 
determine whether the specific opioid detected was used as directed to treat a medical condition or 
                                                 
6 Confidence intervals that include the value 1.0 are not considered to be statistically significant.  
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was used for other purposes. Separating medical use of prescription opioids from other types of use 
in these studies might help to clarify the extent of the risks associated with opioids. 
Fewer studies have examined the crash risk associated with stimulant drugs. The stimulant category 
often includes illicit stimulants such as cocaine and methamphetamine, and is not restricted to the 
legitimate use of amphetamine or methylphenidate for therapeutic purposes. In fact, although not a 
study assessing crash risk, Cox and colleagues (2012) followed a small number of youth with ADHD 
and found their driving improved after starting treatment with amphetamine. Hence, there is no 
evidence that therapeutic use of stimulants increases the risk of crash involvement when used as 
prescribed in the treatment of ADHD.  
Several of the studies cited in previous sections and listed in Appendix E noted an increased risk of 
crash associated with driving after using more than one substance. The findings almost invariably 
show that drivers who combine the use of alcohol with cannabis (Brault et al., 2004; Drummer et al., 
2004; Longo, Hunter, Lokan, White, & White, 2000a, 2000b; Mura et al., 2003; Williams, Peat, Crouch, 
Wells, & Finkle, 1985), benzodiazepines (Barbone et al., 1998; Benzodiazepine/Driving Collaborative 
Group, 1993; Brault et al., 2004; Longo et al., 2000a, 2000b; Lowenstein & Koziol-McLean, 2001) 
or any other psychoactive substance (Brault et al., 2004; Mathijssen & Houwing, 2005; Movig et al., 
2004; Swann, 2000) are at significantly increased risk of crash involvement. The use of more than 
one substance other than alcohol has also been shown to increase the risk of crash involvement 
(Mathijssen & Houwing, 2005; Movig et al., 2004). Importantly, the risks associated with multiple 
substance use are typically higher than those associated with the use of a single substance alone. 
Clearly, drivers who combine more than one psychoactive substance, or a psychoactive substance 
and alcohol pose a serious threat to themselves and other road users.  
Epidemiological studies are rarely able to provide information on whether the substance used was 
taken as prescribed or used illicitly. Using more of one’s medication than prescribed or taking it more 
often, can increase the adverse effects on driving. Using medication prescribed to another person 
can be dangerous for a variety of reasons. In addition, using prescription medications for non-medical 
purposes often involves the ingestion of higher than recommended therapeutic doses or a route of 
administration intended to achieve a quick, intense effect or both. This type of substance use presents 
a number of risks, only one of which is to safe driving. 
Despite the many methodological challenges, the available analytic epidemiological studies provide 
evidence of the increased risk of crash involvement among drivers who consume benzodiazepines, 
non-benzodiazepine hypnotics and opioids. The evidence also shows that the risk associated with 
alcohol increases exponentially with blood alcohol concentration and appears to be substantially 
larger than the risks associated with psychoactive prescription drugs. This difference could be the 
result of methodological differences among studies (particularly compliance with alcohol and drug 
testing), as well as considerable differences in patterns of use. For example, compliance with a 
medically supervised regime of prescription drug use could have overall protective effects in terms of 
crash risk. On the other hand, alcohol consumption is governed primarily by individual choice and 
often exceeds thresholds at which the effects on driving become increasingly profound. The consumption 
of large doses of alcohol combined with the social convention of drinking away from home leads to 
the need for transportation, which places these individuals at risk. It is also clear that the risk of 
crash involvement is higher when drug use is combined with alcohol or other drugs. Virtually every 
study that has examined use of multiple drugs or combined use of drugs and alcohol shows an 
elevated risk of crash involvement. This elevated risk could be the result of the combined effects of 
the substances consumed or the results of unique interactions among the substances that serve to 
increase impairment and crash risk. 
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Discussion and Conclusions 
The experimental research evidence leaves little doubt that psychoactive prescription drugs can 
adversely affect cognitive and motor functions involved in the operation of a motor vehicle. 
Epidemiological studies show that psychoactive prescription drug use among drivers is not uncommon 
and that these drivers often become involved in crashes. However, the evidence pertaining to the 
extent of increased risk of crash involvement associated with the use of psychoactive prescription 
drugs is less consistent. Whereas the weight of the evidence reveals a significant increase in crash 
risk associated with the use of these drugs, there are also studies that fail to find such an increase. 
Overall, the evidence of driver impairment and risk is strong for the use of benzodiazepines, Z-hypnotics 
and opioids. Less evidence is available pertaining to the risks associated with the use of 
amphetamine and antihistamines.  
The lack of consistent, definitive evidence on the road safety risks associated with the use of 
psychoactive prescription drugs is most likely related to the many challenges of the research, all of 
which can have a bearing on the results. For example, differences in the various methodologies used 
to assess risk, the assumptions and limitations of the studies, the type of bodily fluid sample collected, 
the drug testing methods used, the characteristics of the populations studied, and drug use and 
driving practices in the jurisdictions where the studies were conducted can all have a bearing on the 
results. Caution is also warranted in the interpretation of case-control studies that used different 
sample media (blood, urine or oral fluid) or non-equivalent cut-off values in testing for drugs.  
The experimental literature indicates that not all psychoactive prescription drugs within a category 
exhibit the same degree of adverse effects. In epidemiological studies, the small number of drivers 
testing positive for specific drugs, however, often requires that substances with similar types of effects 
be grouped together for analysis. This aggregation of drugs implies that all substances within a 
category are associated with the same degree of risk. Until such time as the research is able to provide 
sufficient evidence on specific substances, differences in the risks associated with individual products 
will remain unknown.  
It is also the case that not all drivers involved in crashes are tested for drugs, nor are drivers selected 
as controls in case-control studies required to participate. Furthermore, when blood samples are 
collected, not all potentially impairing drugs are necessarily included in the toxicology test panel. The 
variation in testing rates and the lack of common procedures in drug testing limits the validity of the 
estimates of the extent to which drugs contribute to serious road incidents. There is a need for 
consistency in the list of drugs that should be tested for in traffic-related cases, along with common 
cut-off values and standard analytic techniques (Farrell, Kerrigan, & Logan, 2007).  
In assessing the evidence, it is imperative to recognize that there are inherent differences between 
the medical use of psychoactive prescription drugs prescribed by a healthcare practitioner for the 
treatment of a medical condition and the use of psychoactive substances for other purposes. Whereas 
medical use of prescription drugs is widely viewed as necessary and beneficial, any other use is 
deemed potentially harmful and dangerous. One of the major factors involved is dose. Although 
medical use can involve high doses, non-medical use of prescription drugs is often associated with 
the use of doses higher than those typically prescribed to treat a medical condition.  
The distinction between medical and non-medical use can become blurred in some situations. For 
example, an individual can begin with a prescription for opioids to relieve chronic pain, but over time 
might develop a dependence on the medication and begin taking more medication than prescribed 
to obtain the same effects. This dependence might lead to seeking alternative sources for the drug. 
Distinguishing the different types of drug use in epidemiological studies is extremely difficult and 
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requires interviews with those using the drugs or inferences about drug concentrations or both. The 
present study recognizes that the epidemiological research often includes both types of drug use.  
Further complicating the interpretation of the research is that in some cases the use of the appropriate 
psychoactive prescription drugs under the supervision of a healthcare practitioner might actually 
serve to improve the ability of a patient to operate a vehicle safely by helping to alleviate the effects 
of the disease (Wingen, Bothmer, Langer, & Ramaekers, 2005). While the rationale is compelling, 
there is limited research evidence supporting widespread offsetting effects of this kind. Future research 
needs to include patient populations in the study sample to determine the effect on their driving 
behaviour that can be attributed to the nature and extent of medications. At this point, generalizations 
should be avoided and evaluations of such effects be conducted on a case-by-case basis.  
The influence of specific risk groups within the population also needs to be considered. For example, 
young and new drivers might be more susceptible to the impairing effects of drugs. Females are 
more likely than males to use anxiolytic medications. Older adults and those with chronic illnesses 
are more likely to take multiple prescription drugs, increasing the risk of adverse effects of drug 
interactions (Canadian Institute for Health Information, 2014; Ramage-Morin, 2009). Further 
research is required to better understand the risks of specific groups and the precautions or 
considerations to help ensure the safe use of medications by these groups. 
The Way Forward 
While acknowledging the limitations of the existing evidence, there is a need to begin implementing 
policies and practices to reduce the risks to all road users as a result of the use of psychoactive 
prescription drugs by drivers.  
One of the initial responses to road safety problems such as impaired driving is often enforcement. 
In Canada, driving while impaired by alcohol or drugs is a criminal offence that carries severe sanctions 
(Canadian Centre on Substance Abuse, 2016). The law makes no distinction between the type of 
substance consumed or the reason for taking it. Driving while impaired by a psychoactive prescription 
medication, whether taken for health reasons or not, is the same offence punishable by the same 
penalties as driving while impaired by alcohol or an illicit substance. From a public safety perspective, it 
does not matter why a driver was impaired, but merely that impairment by alcohol or drugs placed 
the driver and other road users at risk. To some extent, we rely on judges to take such issues into 
account in sentencing. 
Enforcement of impaired driving laws is widespread in Canada. Police services throughout the country 
operate periodic spot check activities to identify impaired drivers and remove them from the road. 
While most would agree that arresting drivers impaired by alcohol or illicit drugs is appropriate and 
warranted, a gentler approach for dealing with drivers who are adversely affected by their prescription 
medication might find favour with many. Short-term administrative licence suspension to immediately 
remove the affected driver from the road might be an appropriate response in most of these cases 
(Canadian Centre on Substance Abuse, 2016). This response could be followed up with a requirement 
to consult with a healthcare practitioner to determine what action should be taken to prevent 
subsequent occurrences of impaired driving. 
Some countries have adopted an approach similar to that taken with alcohol and have established 
illegal drug concentration limits while driving for certain prescription drugs. For example, Norway, 
Denmark and the United Kingdom have set limits on the concentration of several prescription drugs, 
most notably benzodiazepines. Other countries (e.g., Sweden, Germany) have established a limit of 
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zero for some drugs. It is, however, often the case that a valid prescription is sufficient to absolve the 
driver of liability or require evidence that the driver was impaired.  
In the case of psychoactive prescription drugs, enforcement should perhaps take a secondary role 
and the primary response to prevent impaired driving should be prevention. There are many opportunities 
for prevention. At the outset, it should be noted that prescription drugs are highly regulated products. 
From the point of product development, to the prescriber, the pharmacist and even the user, prescription 
drugs are subject to numerous rules and regulations to help ensure these products are used for the 
intended purposes, as well as to prevent or limit adverse effects. Each of these points also provides 
an opportunity for prevention.  
It is incumbent upon product developers and producers to ensure that their products are not only 
effective but safe. This safety requires extensive research and clinical trials to determine and report 
the nature and extent of effects beyond the intended therapeutic effects, often referred to as “side 
effects.” For example, manufacturers must assess the potential effects on an unborn child so that 
physicians can avoid prescribing medications with known teratogenic effects to pregnant females. 
No such systematic testing to determine the extent of adverse effects on one’s ability to operate a 
vehicle is currently required, although manufacturers can report any known effects. Such information 
would be beneficial to guide the prescriber’s choice of medication for their patients who drive. 
In 2000, the U.S. National Transportation Safety Board recommended that the Department of 
Transportation establish a list of approved medications that may be used when operating a vehicle 
(National Transportation Safety Board, 2000). Subsequently, the Department of Transportation 
convened an expert panel to determine if such a list could be developed and indicate which medications 
might pose a hazard to driving. The panel developed a structured, standardized protocol for assessing 
the impairment potential of drugs. This approach would lead to better classification of drugs and 
provide more meaningful information to prescribers and patients about the impact of drugs on driving 
(Kay & Logan, 2011). The U.S. Food and Drug Administration has recently recommended that industry 
adopt this objective approach for evaluating the effects of drugs on driving (U. S. Department of Health 
and Human Services, 2015).  
Government regulatory agencies are charged with the task of ensuring that prescription drugs products 
are both safe and effective. Of the possible adverse effects reported by drug manufacturers, impairment 
potential is not necessarily deemed a key concern unless the drug is known to cause sedation or 
dizziness. However, there is a vast array of impairing effects that goes considerably beyond sedation 
and dizziness. A potential solution is for regulators to require manufacturers to test all products, or 
least those that act on the brain, using the protocol for assessing impairment potential developed by 
the expert panel convened by the U.S. Department of Transportation.  
Standardized testing of all existing psychoactive prescription drugs for their impairment potential is 
an expensive, time-consuming proposition. In the absence of such testing, there have been national 
and international efforts to develop a rating scheme for medicines for potential impairment based on 
an assessment of their pharmacological profile, available experimental research, epidemiological 
findings and clinical experience. Notable among these efforts is the work of the International Council 
on Alcohol Drugs and Traffic Safety (ICADTS) Working Group on Prescribing and Dispensing Guidelines 
for Medicinal Drugs Affecting Driving Performance. This group developed a system for classifying 
medicinal drugs according to their potential for causing driver impairment and provided a series of 
recommendations for implementing the system along with tools to help improve prescribing and 
dispensing practices (Alvarez, deGier, & ICADTS Working Group, 2001). The classification system 
includes a long list of prescription drugs that has since been updated and revised (Alvarez, de Gier, 
Mercier-Guyon, & Verstraete, 2007; de Gier & Alvarez, 2013). Within this classification system, 
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Level I indicates the drug is presumed to be safe or unlikely to produce any adverse effects on 
driving. Level II indicates the drug is likely to produce minor to moderate adverse effects and Level III 
indicates the drug is likely to produce severe effects or is presumed to be potentially dangerous. 
France, Spain and the Netherlands have implemented this three-tier classification scheme for 
prescription drugs by way of a clear, easy-to-understand graphic placed on product packaging and 
inserts to provide the consumer with information about the risk associated with driving after taking 
the medication.  
In addition to the easy-to-understand warnings provided to consumers, this categorization scheme 
for prescription drugs can serve as the basis for mass communication about prescription drug use 
and driving impairment. It can also serve to trigger discussions between the patient and the prescriber 
or pharmacist about the risks of driving while using the medication. The list of prescription drugs with 
their classification also provides prescribers with information about alternative drugs that could be 
used for the same condition, but have less impairment potential for patients who have to drive.  
Consumers also need to be aware of the potential for prescription drugs to affect their ability to 
operate a vehicle safely. Unless specifically told by their healthcare practitioner not to drive after 
taking a particular prescription drug, many might either believe it is safe to do so or simply never 
consider the possibility of their medication having an effect on their driving. Informed decisions 
about the safety of driving while using a prescription drug cannot be made in the absence of 
information on the effects of that drug on the ability to operate a vehicle safely.  
There are several opportunities for consumers to obtain information about the potential impact of 
their prescription drugs on their ability to operate a vehicle safely. The healthcare practitioner is 
generally in the best position to advise the patient about the risks associated with the prescribed 
medication. In addition to knowledge of the drug’s action, the physician typically has details about 
the patient’s social and medical history, as well as other medications being used. The physician and 
pharmacist are also able to consider alternative medications that could be used that have less 
profound effects on driving.  
The potential impact of prescription drugs on driving is an important consideration in deciding on 
which medication is best for the patient. For many, driving has become an essential component of 
their lifestyle. Simply discontinuing driving while taking prescription drugs can be a difficult decision. 
Hence, physicians might sometimes be reluctant to advise patients not to drive even for an initial 
period of time when starting a new medication or increased dose of a medication for fear that the 
patient will choose not the take the prescription drugs or only take it when convenient, rather than 
abstain from driving. The concern is a legitimate one and is best dealt with through a discussion 
between physician and patient. 
Pharmacists also have an opportunity to provide further information about the anticipated effects of 
medications. In addition to verbal cautions, many pharmacists also provide written descriptions of 
contraindications, how to take medications and adverse effects to be wary of, including effects on 
cognition and psychomotor performance. Some prescription drugs come with a label on the package 
warning about the potential dangers associated with driving while taking the medication. Such warnings, 
however, can be vague and leave the consumer to decide whether to drive based on their perception 
of how the prescription drug is affecting them. Granted, some consumers will heed the warning and 
take appropriate caution in making decisions about driving. Unfortunately, the adverse effects of 
prescription drugs are not always apparent to the user. Others will discount the effects and rationalize 
driving. Stronger warnings and direct guidance about avoiding driving would be in order. 
In conclusion, there is a need for ongoing research to better understand the adverse effects of 
various psychoactive prescription drugs on driving, the circumstances under which impairment is 
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likely to occur and the characteristics of those at greatest risk. Even in the absence of a complete 
understanding of the role of prescription drugs in road crashes, there is sufficient evidence to 
advance the state of prevention activities. In this context, there is need for interdisciplinary discussion 
and consultation involving all those with an vested interest in this area (e.g., regulators, prescribers, 
pharmacists, enforcement, policy makers and consumers) in a process that will use available 
resources, knowledge and experience to develop and implement an integrated set of policies and 
practices to reduce the risks associated with the use of psychoactive prescription drugs by drivers. 
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Appendix A 
Search Terms 
 driv*, driving simulator, automobile driv*, motor vehicle driv*, road tests 
 drugs and driving, impair*, drug, effects of drugs, influence of drugs, driver impairment  
 central nervous system agents, depressants, hypnotic, stimulants, opioids, narcotic 
analgesic, antihistamine, amphetamine, opiate, benzodiazepine, anxiolytic, Z-drug, Z-
hypnotic, psychotropic, psychoactive, prescription drug  
 roadside survey, motor vehicle crash, crash risk, relative risk, injury, fatal crash, case-control, 
drivers at risk, crash-involved  
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Appendix B 
Drug Use among Road Users: Roadside Surveys 
Study Location Sample Method Results 
Assum et al. 
(2005) 
Norway N=410 
All days/all times  
Oral fluid samples collected 
by police (required) 
Opiates 0.2% 
Benzodiazepines 0.2% 
Cannabis 0.5% 
Alcohol 0.0% 
Behrensdorff 
& Steentoft 
(2003) 
Denmark  
N=961 (drivers 
suspected of illegal 
driving were not 
included) 
70% daytime hours  
Mainly rural 
Oral fluid sample requested 
by police 
1.3% positive for illegal drugs 
0.7% positive for 1 or more 
benzodiazepines 
Beirness & 
Beasley 
(2009)  
British Columbia, 
Canada 
N=1,533  
78% provided oral 
fluid (N=1,197)  
9 pm–3 am, Wed.–Sat.  
Alcohol 8.1% 
Cannabis 4.6% 
Cocaine 4.6% 
Opioids 0.9%  
Beirness & 
Beasley 
(2011) 
British Columbia, 
Canada  
N=2,306  
71% provided oral 
fluid (N=1,781)  
9 pm–3 am, Wed.–Sat. 
Alcohol 9.9% 
Cannabis 4.5% 
Cocaine 2.3% 
Opioids 1.2% 
Beirness & 
Beasley 
(2012) 
British Columbia, 
Canada 
N=2,513  
70% provided oral 
fluid (N=1,757)  
9 pm–3 am, Wed.–Sat. 
Alcohol 6.5% 
Cannabis 4.4% 
Cocaine 3.3% 
Opioids 0.8% 
Beirness, 
Beasley, & 
McClafferty 
(2015) 
Ontario, Canada 
N=2,443  
80.7% provided 
oral fluid  
9 pm–3 am, Wed.–Sat. 
Alcohol 4.0% 
Cannabis 7.7% 
Stimulants 2.2% 
Opioids 1.5% 
Berning, 
Compton, & 
Wochinger 
(2015) 
United States  
N=11,100  
71% provided oral 
fluid (N=7881) 
42.2% provided 
blood (N=7898)  
Fri. daytime 
Fri.–Sat. nights  
Weekend nights: 
Any illegal drug 15.2% 
Only medications 7.3% 
Weekdays: 
Any illegal drug 12.1% 
Only medications 10.3% 
Assum et al. 
2005  
Scotland  N=1,312 
All days, all times 
Oral fluid samples 
Police screened drivers for 
impairment  
Cannabis 3.14% 
Amphetamines 0.49% 
Ecstasy 4.10% 
Cocaine 0.98% 
Opiates 0.02% (excludes 
codeine) 
Codeine 1.34% 
Dussault, 
Lemire, 
Bouchard, & 
Brault (2000) 
Quebec, Canada 
N=5,509 41.4% 
compliance  
All days, all times 
Urine samples 
Cannabis  5.2% 
Benzodiazepines 3.7% 
Cocaine 1.1% 
Opiates 1.1% 
Barbiturates 0.4% 
Amphetamines < 0.1% 
Fierro, 
Gonzalez-
Luque, Segui-
Gomez, & 
Alvarez (2015) 
Spain  
N=3,302  
(2008–2009) 
Oral fluid (on-site analysis) 
Mandatory tests 11 months 
Cannabis 5.28% 
Cocaine 1.28% 
Amphetamines 0.06% 
Opiates 0.14% 
Benzodiazepines 0.17% 
Alcohol > .05 BAC 4.92% 
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Fierro et al. 
(2015) 
Spain  
N=2,932 
(2013) 
Oral fluid (on-site analysis) 
Mandatory tests April and 
November  
Cannabis 3.13% 
Cocaine 0.87% 
Amphetamines 0.12% 
Opiates 0.03% 
Benzodiazepines 0.09% 
Alcohol > .05 BAC 3.41% 
Gjerde et al. 
(2008) 
Norway  N=10,816  
All days, all times  
Oral fluid 
Zopiclone 1.4% 
Benzodiazepines 1.4% 
Codeine 0.8% 
THC 0.6% 
Amphetamines 0.3% 
Cocaine 0.1% 
Gjerde et al. 
(2014) 
Norway  N=2,038  
Fri.–Sat., 12 pm–12 am 
Oral fluid  
Amphetamines 0.1% 
Cannabis 1.0% 
BDZ/Zopiclone 1.7% 
Opioids 0.4% 
Alcohol 0.2% 
Brazil  N=3,326 
Amphetamines 0.5% 
Cannabis 0.5% 
BDZ/Zopiclone 1.0% 
Opioids 0.0% 
Alcohol 2.7% 
Houwing et al. 
(2011) 
13 European 
countries 
N=48,542 
Week days 2 pm–9.59 pm 
Week nights 10 pm–3.59 am 
Weekend days 4 pm–9.59 pm 
Weekend nights 10 pm–
3.59 am 
Benzodiazepines 0.9% (0.14–
2.73) 
Opioids 0.35% (0.0–1.79) 
Z-drugs 0.09% (0.0–0.69) 
Alcohol 3.48% (0.15–8.59) 
THC 1.32% (0.0–5.99) 
(numbers in brackets are the 
range across countries) 
Krüger, Schulz, 
& Magerl 
(1995) 
Germany 
(Unterfranken)  
N=2,234  
All days, all times 
Oral fluid samples 
Benzodiazepines 3% 
Illicit drugs 1% 
1/3 of drug cases also 
positive for alcohol 
Lacey et al. 
(2009) 
United States  
N=8,384 
(nighttime) 
Fri.–Sat., 10 pm–12 am, 
1 am–3 am  
Oral fluid 71%  
Blood 39% 
Benzodiazepines 2.0% 
Opioids 2.95% 
Amphetamine 0.86% 
Cannabis 7.66% 
Alcohol 12.4% 
N=2,525 (daytime) 
Fri. 9:30 am–11:30 pm, 
1:30 pm–3:30 pm  
Oral fluid 73%  
Blood N/A 
Benzodiazepines 2.26% 
Opioids 1.49% 
Amphetamine 0.56% 
Cannabis 4.46% 
Alcohol 1.0% 
Mathijssen & 
Houwing 
(2005) 
Netherlands  N=3,799  
All days, all times 
Urine samples (N=2,873) 
Blood samples (N=501)  
Alcohol 2.3% 
Cannabis 4.5% 
Benzodiazepines 2.1% 
Amphetamines 0.03% 
Cocaine 0.7% 
Opiates 6.6% (includes 
codeine) 
Pechansky et 
al. (2010) 
Brazil  N=3,492 
Fri.–Sat. 
12 pm–12 am  
Benzodiazepines 1.04% 
Amphetamines 1.2% 
Cannabis 1.5% 
Alcohol 4.8% 
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Drug Use among Crash-Involved Drivers 
Study Location Sample Method Results 
Ahlm, Björnstig, 
& Oström 
(2009) 
Northern 
Sweden 
N=102 hospitalized 
drivers 
N=56 fatalities 
Fatalities: blood & urine 
Injured: blood (up to 6 
hours post-crash) 
Substance Fatal Injured 
Alcohol 38% 21% 
Pharma* 7% 13% 
Illegal drugs 9% 4% 
Combinations 5% 7% 
* benzodiazepines, opioids, 
antidepressants 
Ahlner, 
Holmgren, & 
Jones (2013) 
Sweden 
N=895 driver 
fatalities 
Blood samples 
Diazepam 1.8% 
Zopiclone 1.6% 
Amphetamine 3.3% 
Cannabis 3.5% 
Alcohol 20.8% 
Beirness, 
Beasley  
& Boase (2013) 
Canada N=9,547  
Fatally injured drivers 
Blood drawn within 2 
hours  
Sedative-hypnotics 11.2% 
Opioids 5.4% 
CNS Stimulants 8.6% 
Cannabis 16.6% 
Alcohol 38.5% 
Brady & Li 
(2014) 
United States 
(6 states) 
N=7,159 drivers 
killed in crashes  
(2007–2010) 
Blood samples 
Driver died within 1 
hour of crash 
Substance Male Female 
Sedative-hypnotics 3.2% 4.8% 
CNS stimulants 9.5% 8.9% 
Opioids 4.0% 7.6% 
Cannabis 12.3% 7.5% 
Alcohol 43.7% 27.7% 
 
Brault, 
Dussault, 
Bouchard, & 
Lemire (2004) 
Quebec, 
Canada 
N=512 fatally injured 
drivers 
Blood tests 
Benzodiazepines 10.4% 
Opiates 1.8% 
Amphetamines 0.8% 
Cannabis 19.7% 
Alcohol found in 47.5% of drug 
cases 
Carmen del Río, 
Gómez, 
Sancho, & 
Alvarez (2002) 
Spain 
N=5,745 fatally 
injured drivers 
Blood samples  
Benzodiazepines 3.4% 
Opiates 3.2% 
Amphetamines 1.2% 
Alcohol 43.8% 
Cannabis  2.2% 
Drummer et al. 
(2004) 
Australia 
N=3,398 drivers 
killed in crash 
Blood samples 
Benzodiazepines 4.1% 
Opioids 4.9% 
Stimulants 4.1% 
Other psychoactive drug 2.7% 
Cannabinoids 13.5% 
Alcohol 29.1%  
Gerostamoulos, 
et al. (2002) 
Melbourne, 
Australia 
N=358 crash victims 
at trauma centre 
Blood samples 
Benzodiazepines 14% 
Opiates 10% 
Barbiturates 2% 
Amphetamines 12% 
Cannabis 36% 
Gjerde, 
Christophersen, 
Normann, & 
Mørland (2011) 
Norway 
N=196 fatally injured 
drivers (59% of the 
total) 
Blood samples 
Benzodiazepines 11.8% 
Opioids 1.5% 
Amphetamine 4.6% 
Cannabis 4.6% 
Alcohol 25.0%  
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Jeffery, 
Hindmarsh, & 
Mullen (1996) 
Canada N=391 fatalities 
Incidence of drugs 
among cases submitted 
to forensic labs  
Benzodiazepines 21.4% 
Stimulants 14.5% 
Opiates 8.2% 
Barbiturates 3.1% 
Jones, 
Kugelberg, 
Holmgren, & 
Ahlner (2009)  
Sweden  N=1403  
Drivers killed in crashes 
Blood and urine  
Benzodiazepines 6.6% 
Zopiclone 0.9% 
Opiates/Opioids 4.9% 
Amphetamines 2.8% 
Cannabis 2.4% 
Alcohol 22.4% 
Legrand, 
Houwing, 
Hagenzieker, & 
Verstraete, 
(2012) 
Belgium  N=348  
Injured drivers admitted 
to ER 
Blood samples  
Benzodiazepines 7.3% 
Zolpidem/Zopiclone 1.8% 
Opioids 3.9% 
Amphetamines 2.6% 
Cannabis 7.6% 
Alcohol 42.5%  
Netherlands N=187 
Injured drivers admitted 
to ER 
Blood samples 
Benzodiazepines 0.0% 
Zolpidem/Zopiclone 0.5% 
Opioids 0.5% 
Amphetamines 2.2% 
Cannabis 0.5% 
Alcohol 29.6% 
Longo, Hunter, 
Lokan, White, & 
White (2000a) 
South Australia 
N=2,500 injured 
drivers 
Incidence of drugs 
among injured drivers 
Benzodiazepines 2.7% 
Stimulants 1.3% 
Cannabis 10.8% 
Maio et al. 
(2000) 
Michigan, USA 
N=708 motor vehicle 
crash victims 
Frozen serum samples 
from a previous study 
tested specifically for 
benzodiazepines 
Benzodiazepines 3% 
(60% also positive for alcohol)  
Mercer & 
Jeffery (1995) 
British 
Columbia 
N=227 fatally injured 
drivers 
Blood samples  
Diazepam 5% 
Cocaine 4% 
Alcohol 48%  
Cannabis 13% 
Papadodima et 
al. (2008) 
Southern 
Greece 
N=3,167 crash-
involved drivers 
Blood samples for 
alcohol 
Urine samples for drugs  
Benzodiazepines 4% 
Opiates 4% 
THC 4% 
Alcohol 29% 
Romano & 
Pollini (2013) 
United States N=16,942 
Fatally injured drivers in 
single vehicle crashes 
who died at the scene 
and were tested for 
alcohol and drugs 
Sedative-hypnotics 1.5% 
Opioids 2.1% 
CNS Stimulants 7.2% 
Other 4.1% 
Multi-drug 4.1% 
Cannabis 7.1% 
Alcohol 45.1% 
Ricci et al. 
(2008) 
Italy 
N=100 crash victims  
56 drivers 
15 passengers 
12 bicyclists 
17 pedestrians 
Blood for alcohol 
Urine for drugs 
Benzodiazepines 18% 
Opiates 6% 
THC 9% 
Alcohol 31% 
Smink et al. 
(2005) 
Netherlands 
N=993 crash 
involved drivers 
Blood samples (74% 
test rate) 
Benzodiazepines 10.3% 
Opiates 4.2% 
Cannabis 16.9% 
Alcohol 64.5% 
Stoduto et al. 
(1993) 
Toronto, 
Canada  
Injured victims in 
motor vehicle 
collisions N=854 
Blood & urine samples  
Benzodiazepines 12% 
Cocaine 5%  
Morphine 5% 
Cannabinoids 14% 
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Walsh et al. 
(2005)  
Maryland, USA  
N=108 injured drivers 
at trauma centre  
Urine  
Amphetamines 0.9% 
Methamphetamine 5.6% 
Opiates 10.2% 
Barbiturates 3.7% 
Alcohol 30.6% 
Cannabis 26.9%  
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Appendix D 
Drug Use among Crash-Involved Drivers: Results from 
DRUID 
  (a) Drug-Positive Seriously Injured Drivers (%) 
DRUG Belgium Denmark Finland Italy Lithuania Netherlands 
Benzodiazepines 7.3 6.7 10.2 0.7 3.6 0 
Zopiclone/Zolpidem 1.7 1.2 3.8 0 0 0.5 
Opiates 3.9 4.7 4.0 5.8 8.1 0.5 
Cannabis (THC) 7.6 1.3 5.7 3.7 0.5 0.5 
Alcohol (≥10 mg/dL) 42.5 19.7 32.1 23.1 17.7 29.6 
  (b) Drug-Positive Fatally Injured Drivers (%)  
  Finland Norway Portugal Spain     
Benzodiazepines 13.3 9.7 1.8 3.9   
Zopiclone/Zolpidem 3.0 4.4 0 3.2   
Opiates 2.1 1.7 2.1 4.1   
Cannabis (THC) 1.3 6.1 0 1.3   
Alcohol (≥10 mg/dL) 31.4 25.4 44.9 19.0   
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Appendix E 
Studies Assessing the Risks Associated with Drugs in 
Crashes 
Study Country Sample Method Results 
Barbone et al. (1998) 
United 
Kingdom 
N=1,731 18 and older 
drivers involved in 
road-traffic accident 
taking psychoactive drug 
during study period 
Case-crossover study 
Benzodiazepines OR= 1.62 
(risk greater for drivers 30 and 
younger, at fault, and with a  
positive alcohol breath test) 
Benzodiazepine/Driving 
Collaborative Group 
(1993) 
France 
N=2,852 injured 
drivers 
Responsibility analysis 
blood samples 
Benzodiazepines OR=0.96  
(0.8–1.2)  
Benzodiazepines + alcohol 
OR=7.2 (3.4–15.2) 
Brault, Dussault, 
Bouchard, & Lemire 
(2004) 
Quebec, 
Canada 
N=512 fatally injured 
drivers 
N=5,931 drivers 
tested at roadside 
(1) Case-control 
(2) Responsibility 
analysis 
Urine samples 
Substance 
Case-
control 
Resp. 
BZD 3.9 2.5 
Opioids 3.1 3.2 
Alcohol>0.8 69.9 32.6 
 
Compton & Berning 
(2015) 
United States 
(Virginia 
Beach) 
N=3,095 crash-
involved drivers 
N=6,190 controls 
Case-control  
Sedatives OR=1.19 (0.86–1.64) 
Stimulants OR=0.92 (0.70–1.19) 
Opioids OR=1.17 (0.87–1.56) 
Drummer et al. 
(2004) 
Australia 
N=3,398 drivers killed 
in crash 
Responsibility analysis 
blood samples 
Benzodiazepines OR=1.27 . 
Drummer (1995) Australia 
N=1,052 fatally 
injured drivers 
Responsibility analysis 
blood samples 
Stimulants OR=2.0 
Benzodiazepines OR=2.0  
Opiates OR=2.0 
Alcohol OR=7.6  
Dubois, Bédard, & 
Weaver (2010) 
United 
States 
N=2,541 opioid 
positive cases 
N=69,485 controls 
Drivers involved in fatal 
crashes (all had 0 BAC) 
Responsibility analysis 
using unsafe driving 
action as a proxy for 
responsibility 
Opioids OR=1.72 (1.45-2.03) 
Opioids with Depressants 
OR=1.31 (1.03–1.67) 
Dubois, Bédard, & 
Weaver (2008)  
United 
States  
N=72,026 drivers 
involved in fatal 
crashes (BAC=0) 
Responsibility analysis 
using unsafe driving 
action as a proxy for 
responsibility  
Benzodiazepine short acting 
OR=1.02 (0.73–1.42)  
Benzodiazepine intermediate 
acting OR=1.53 (1.20–1.96) 
Benzodiazepine long acting 
OR=1.54 (1.25-1.66)  
Dussault, Brault, 
Bouchard, & Lemire 
(2002) 
Quebec, 
Canada 
N=354 fatally injured 
drivers 
N=5,931 drivers at 
roadside 
Case-control 
Responsibility analysis 
Urine tests for controls 
Blood + urine tests for 
cases 
Substance 
Case-
control 
Resp. 
Cannabis 2.2 1.2 
Cannabis + 
alcohol 
8.5 2.5 
Cocaine 4.9 – 
BZD 2.5 3.6 
 
The Effects of Psychoactive Prescription Drugs on Driving 
Canadian Centre on Substance Abuse • Centre canadien de lutte contre les toxicomanies  Page 43 
Study Country Sample Method Results 
Engeland, Skurtveit, & 
Morland (2007) 
Norway 
N=12,865 drivers in 
personal injury crashes 
Pharmacoepidemiological 
SIR=Standardized incident 
ratio 
Within first 7 days (men) 
Benzodiazepines short acting 
SIR=4.1 (2.6–6.2) 
Benzodiazepines long acting 
SIR=3.1 (2.5–3.8) 
Opioids    SIR=2.0 (1.5–2.5) 
Within first 14 days (men) 
Benzodiazepines short acting 
SIR=3.2 (2.2–4.5) 
Benzodiazepines long acting  
SIR=2.7 (2.3–3.2) 
Opioids SIR=1.9 (1.6–2.3) 
Gjerde, 
Christophersen, 
Normann, & Mørland 
(2011) 
Norway 
N=204 driver fatalities 
N= 10,540 roadside 
controls 
Case-Control  
Blood for fatalities 
Oral fluid for controls 
Benzodiazepines  OR=11.4  
(6.7–19.3) 
Benzodiazepines alone OR=1.6 
(0.5–5.2) 
Opioids OR=5.7 (2.0–16.2) 
Zopiclone OR=5.4 (2.3–12.6) 
Zopiclone only OR=2.6 (0.9–7.6) 
Gomes et al. (2013) 
Ontario, 
Canada 
N=1,930 road trauma 
cases 
N=1,819 controls with 
opioid prescription 
< 65 years of age 
Pharmacoepidemiological 
Opioid low dose  OR=1.21  
(1.02–1.42) 
Opioid mod dose OR=1.29 
(1.06–1.57) 
Opioid high dose OR=1.42  
(1.15–1.76) 
Opioid very high dose  OR=1.23 
(1.02–1.49) 
Gustavsen, Mørland, 
& Bramness (2006) 
Norway 
N=3.9 million persons 
prescribed 
medications 
N=129 crashes 
Pharmacoepidemiological 
SIR=Standardized 
incident ratio 
Zopiclone SIR=2.3 (2.0–2.8)  
Zolpidem SIR=2.2 (1.4–3.4)  
Nitrazepam SIR=2.7 (1.8–3.9)  
Flunitrzepam SIR=4.0 (2.4–6.4)  
Hemmelgarn, Suissa, 
Huang, Bolvin, & 
Pinard (1997) 
Quebec, 
Canada 
N=5,579 67–84 year 
old drivers involved in 
a crash where at least 
1 person was injured 
N=18,490 controls 
Nested case-control 
design (prescription 
information obtained 
from the provincial 
agency responsible for 
administering healthcare 
services) 
Benzodiazepine long acting 
OR=1.28 
Benzodiazepine long acting 
OR=1.45 
(first 7 days of use) 
Benzodiazepines long acting 
OR=1.26  
(61–365 days use) 
Benzodiazepine short acting 
OR=0.96  
Li, Brady, & Chen 
(2013) 
United 
States 
N=737 drivers in fatal 
crashes 
National Roadside 
Survey  
Case-control 
Depressants OR=4.83  
(3.18–7.21) 
Narcotics OR=3.03 (2.00–4.48) 
Stimulants OR=3.57 (2.63–4.76) 
Longo, Hunter, Lokan, 
White, & White 
(2000b) 
South 
Australia 
N=2279 injured 
drivers 
Responsibility analysis 
(blood samples) 
Benzodiazepines only OR=2.0 
Benzodiazepines + alcohol 
OR=13.4 
Stimulants only OR=2.0 
Alcohol only OR=8.0 
Movig et al. 
(2004) 
Netherlands 
N=110 injured drivers 
N=816 controls 
randomly stopped on 
public roads 
Case-control design blood 
and/or urine samples 
Benzodiazepines OR=5.05 
(1.82–14.04) 
Opiates OR=2.35 (0.87–6.32) 
Mura et al. 
(2003) 
France 
N=900 injured drivers 
N=900 ER patients 
Case-control 
Blood samples 
Morphine OR=8.2 
Benzodiazepines OR=1.7  
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Neutel (1995) Saskatchewan 
N=147,726 drivers 
with prescription for 
benzodiazepines 
N=97,862 controls 
Pharmacoepidemiology 
(no toxicology) 
Benzodiazepine short acting 
OR=3.9 within 4 weeks 
Benzodiazepine short acting 
OR=6.5 within 2 weeks 
Benzodiazepine long acting 
OR=2.5 within 4 weeks 
Benzodiazepine long acting 
OR=5.6 within 2 weeks 
Other sedatives OR=2.2  
 
